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Abstract Apoptosis-inducing factor (AIF) is encoded by one
single gene located on the X chromosome. AIF is ubiquitously
expressed, both in normal tissues and in a variety of cancer cell
lines. The AIF precursor is synthesized in the cytosol and is
imported into mitochondria. The mature AIF protein, a
flavoprotein (prosthetic group: flavine adenine dinucleotide) with
significant homology to plant ascorbate reductases and bacterial
NADH oxidases, is normally confined to the mitochondrial
intermembrane space. In a variety of different apoptosis-inducing
conditions, AIF translocates through the outer mitochondrial
membrane to the cytosol and to the nucleus. Ectopic (extra-
mitochondrial) AIF induces nuclear chromatin condensation, as
well as large scale (V50 kb) DNA fragmentation. Thus, similar
to cytochrome c, AIF is a phylogenetically old, bifunctional
protein with an electron acceptor/donor (oxidoreductase) func-
tion and a second apoptogenic function. In contrast to
cytochrome c, however, AIF acts in a caspase-independent
fashion. The molecular mechanisms via which AIF induces
apoptosis are discussed. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Apoptosis is characterized by the permeabilization and/or
rupture of the outer mitochondrial membrane [1^3]. As a
result, proteins normally con¢ned to the intermembrane space
are translocated to non-mitochondrial structures [4^6]. Their
translocation from an orthotopic (mitochondrial) to an ec-
topic (extra-mitochondrial) localization then triggers catabolic
reactions which give rise to the apoptotic phenotype. As an
example, cytochrome c redistributes from the mitochondrion
to the cytosol [4] and triggers the formation of a caspase-9/
caspase-3 activating complex, the apoptosome, which recruits
several cytosolic factors such as Apaf-1 and ATP [7]. Several
additional mitochondrial intermembrane proteins (heat shock
protein 10, SMAC, and several pro-caspases, in particular
pro-caspases-9) are released together with cytochrome c and
stimulate the ‘apoptosome’ [7^10]. Once released from the
apoptosome, caspase-3 triggers activation of yet another pro-
tein, caspase activated DNAse (CAD, also called DNA frag-
mentation factor, DFF), which mediates oligonucleosomal
DNA fragmentation [11^14]. It would be an oversimpli¢ca-
tion, however, to assume that the pathway leading from mi-
tochondrial membrane permeabilization to nuclear apoptosis
relies exclusively on apoptosome formation and caspases.
Thus, the mitochondrial intermembrane space contains a pro-
tein that provides a direct, caspase-independent molecular link
between mitochondria and nuclei : apoptosis-inducing factor
(AIF) [15,16]. This review will summarize our current knowl-
edge on the molecular and cellular biology of AIF.
2. The AIF protein
Our group published in 1996 [17,18] that the mitochondrial
intermembrane protein fraction contains an activity which
su⁄ces to force isolated HeLa nuclei to adopt an apoptotic
morphology and to lose at least part of their DNA content.
We coined this activity as ‘apoptosis-inducing factor’ (AIF).
Based on a semi-automated cyto£uorometric assay designed
to measure the frequency of subdiploid nuclei exposed to mi-
tochondrial proteins [19], we puri¢ed a protein which main-
tains its bioactivity in the presence of the pan-caspase inhib-
itor Z-VAD.fmk [8]. Cloning of the full-length cDNAs
corresponding to mouse AIF (612 amino acids) and human
AIF (613 aa) [15] revealed that AIF is strongly conserved
between the two mammalian species (92% aa identity in the
whole protein). The mouse AIF cDNA codes for a protein
which is organized in three domains: (1) an amino-terminal
mitochondrial localization sequence (MLS) of 100 amino
acids; (2) a spacer sequence of 27 amino acids; and (3) a
carboxyterminal 485 amino acid oxidoreductase domain
with strong homology to oxidoreductases from other verte-
brates (X. laevis), non-vertebrate animals (C. elegans, D. mel-
anogaster), plants, fungi, eubacteria, and archaebacteria [20]
(Fig. 1).
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 7 3 1 - 2
*Corresponding author. 19 rue Guy Mo“quet, B.P. 8, F-94801 Ville-
juif, France. Fax: (33)-1-4958 3509.
E-mail: kroemer@infobiogen.fr
Abbreviations: AIF, apoptosis-inducing factor; CAD, caspase-acti-
vated DNAse; v8m, mitochondrial transmembrane potential; FAD,
£avine adenine dinucleotide; GFP, green £uorescent protein; MLS,
mitochondrial localization sequence; NAD, nicotine adenine dinu-
cleotide; NLS, nuclear localization sequence; PT, permeability tran-
sition
FEBS 23854 30-6-00 Cyaan Magenta Geel Zwart
FEBS 23854FEBS Letters 476 (2000) 118^123
Among eukaryotic proteins with known enzymatic func-
tion, the strongest homology with AIF was found for plant
semidehydroascorbate and ascorbate reductases, which are
£avoproteins [20]. Functionally important amino acids in-
volved in the interaction with the prosthetic groups (£avin
adenine dinucleotide (FAD) and nicotinamide adenine dinu-
cleotide (NAD)) are strongly conserved between AIF and bac-
terial NADH oxidoreductases [20]. Accordingly, natural AIF
puri¢ed from mouse liver mitochondria was found to be an
FAD-binding protein and recombinant AIF can be refolded
in vitro, in the presence of FAD, resulting in stable FAD
binding (unpublished results). Recombinant AIF precursor
protein does not spontaneously incorporate FAD when puri-
¢ed from inclusion bodies of Escherichia coli. In contrast,
recombinant AIF proteins lacking the MLS (AIF v1^100,
mature AIF) or the MLS and part of the spacer region
(AIF v1^120) spontaneously incorporate FAD when ex-
pressed in E. coli. Full-length AIF precursor protein (without
FAD), AIF v1^100, and AIF v1^120 (both with FAD) all
induced nuclear apoptosis when added to puri¢ed HeLa nu-
clei (Fig. 1). This indicates that the oxidoreductase activity
(which depends on the presence of the prosthetic group) is
not relevant to the apoptogenic e¡ect of AIF. However, dele-
tion mutations a¡ecting parts of the oxidoreductase domain
(v1^351, v155^612, v538^612) abolished the apoptogenic po-
tential of AIF (Fig. 1), indicating that at least some of the
structural features of the oxidoreductase domain are impor-
tant for the apoptogenic e¡ect of AIF [15].
3. Localization and expression pattern of the AIF gene
Fluorescent in situ hybridization (FISH) with an AIF
cDNA revealed that only one single mouse chromosome hy-
bridizes with the AIF cDNA (Fig. 2A,B). The AIF gene is
localized within mouse X chromosome region A6 (Fig. 2C),
which is syntenic to the human X chromosome region Xq25^
26, where the human AIF gene is located (EMBL accession
no. Z81364). FISH analyses con¢rmed that human cells only
contain one AIF or AIF-related gene, on Xq (not shown).
Based on Northern blot analysis using the full-length AIF
Fig. 1. Structure^function relationship of AIF. The scheme delin-
eates the functional properties (mitochondrial import in vitro, FAD
binding, apoptogenic e¡ect on puri¢ed HeLa nuclei) of recombinant
proteins corresponding to the AIF precursor (which has an N-termi-
nal mitochondrial localization sequence, MLS), mature AIF (which
lacks the MLS), as well as several truncation or deletion mutations.
NLS denotes nuclear localization sequence. Numbers refer to the
amino acids position of the mouse AIF sequence.
C
Fig. 2. Expression pattern of AIF at the DNA, RNA, and protein
levels. (A^C) chromosomal localization of the AIF gene. Fluores-
cent in situ hybridization (FISH) of AIF (red £uorescence, B) on a
male mouse karyogram counterstained with DAPI (blue £uores-
cence, A). The detailed position of the AIF gene was mapped to
chromosome X region A6 (10 determinations with identical results,
C). (D) mRNA expression pattern of AIF. An AIF cDNA probe
was hybridized to a Northern blot of polyadenylated RNA from
human pancreas (1), kidney (2), skeletal muscle (3), liver (4), brain
(6), placenta (5), and heart (7). (E) Protein expression pattern of
AIF. An antiserum raised against aa 151^200 of mAIF was used to
detect AIF protein contained in puri¢ed mitochondria from mouse
liver (1), kidney (2), heart (3), brain (4), or spleen (5). Control blots
performed in the presence of the immunogenic peptides covering aa
151^200 yield negative results for liver mitochondria (Co.).
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cDNA as a probe, one single 2.4-kb AIF mRNA species was
found to be expressed ubiquitously in human tissues (Fig.
2D). This ¢nding was corroborated at the protein level for
mouse tissues using an antibody raised against aa 151^200
of AIF, which recognizes a single V57-kDa protein (Fig.
2E). Thus, despite the fact that several AIF cDNA variants
are listed in the GenBank data base (e.g. AF100928,
AL049704, and AL049703 for human AIF), suggesting alter-
native splicing of the primary AIF transcript, only one dom-
inant AIF mRNA species and protein species can be discerned
Fig. 3. Tissue distribution of AIF in human tissues. Immunohistochemichal stainings were performed on normal human tissue sections with the
AIF (or hsp60) antibody revealed with Fast Red (Dako Envision method) and then counterstained with hematoxylin. AIF appears in red and
nuclei in dark blue. (A) Distribution of a mitochondrial marker (hsp60, left panel) and AIF (right panel) localizations on normal kidney sec-
tions (U200). The most abundant AIF staining is in tubular epithelial cells predominantly in proximal tubules. At close inspection, all cell
types contained an intracytoplasmic AIF staining. Note the strong correlation between AIF staining intensity and the expression level of the
mitochondrial proteins hsp60. (B) From left to right and top to bottom. Cardiomyocyte location of AIF (U400), the renal arcuate artery show-
ing a predominant AIF staining in the myocytes of the media (U200), AIF in skeleton muscle myocytes (U200), normal bone marrow showing
a strong intracytoplasmic staining in red cell line (predominantly in erythroblasts) and weaker in granular cell line (U400), AIF staining of epi-
thelial cells in duodenum and in Lieberku«hn crypts of the colon (U200 for both), AIF location in hepatocytes (U400) and predominant AIF
staining in the stratum Malpighii of the skin (U400).
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by Northern and Western blot analyses. Comparative cytohis-
tochemical staining with antibodies speci¢c for AIF and for
the mitochondrial matrix protein hsp60 reveal an overlapping
expression pattern, as well as an identical subcellular distribu-
tion in histological sections of human tissues (exempli¢ed for
the renal cortex in Fig. 3A). At close inspection, all cell types
were found to express AIF, and a strong correlation between
AIF staining intensity and the expression level of mitochon-
drial proteins such as hsp60 (Fig. 3A) was observed. AIF
protein was detected in numerous human tissues including
muscle, bone marrow, intestine, liver, and skin (Fig. 3B). As
to be expected, AIF was found to be localized in mitochon-
drion-rich areas (e.g. in the intersegmental areas of striated
muscle or in the basal perinuclear area of colon epithelial
cells) (Fig. 3B). Hence, AIF is a ubiquitous protein con¢ned
to mitochondria, at least in healthy normal tissues. AIF was
also found to be expressed in numerous human cancer cell
lines (s 65 lines tested thus far). Thus far, we have not suc-
ceeded in identifying a single cell line or primary tumor in
which the AIF protein would be completely absent. This
may indicate that, in addition to its apoptogenic function,
AIF exerts a yet-to-be-de¢ned vital function, perhaps linked
to its oxidoreductase function.
4. Subcellular localization of AIF in healthy versus apoptotic
cells
In vitro assays performed with the primary transcription/
translation product of full-length AIF cDNA revealed that
AIF is imported into mitochondria and that this import de-
pends on the presence of the N-terminal MLS [15]. This result
has been recently con¢rmed in intact cells. Transient trans-
fection of COS cells with green £uorescent protein (GFP)
fused to the C-terminus of AIF to generate a chimeric AIF^
GFP protein, targets GFP to mitochondria [21]. In contrast, a
truncated AIF^GFP fusion protein in which the N-terminal
MLS was removed (AIF^GFPv1^100), exhibited a di¡use cy-
toplasmic distribution of GFP, comparable to that obtained
with GFP alone [21,22]. Similarly, immuno£uorescence stain-
ing of untransfected cells with an AIF-speci¢c antiserum
(raised against amino acids 151^200) revealed that endoge-
nous AIF is exclusively found in mitochondria [15,16]. Sub-
cellular and submitochondrial fractionation corroborated
that, in healthy cells, AIF is con¢ned to the mitochondrial
intermembrane space [15].
6
Fig. 4. Redistribution of AIF during in vitro chemotherapy. SHEP
neuroblastoma cells transfected with the Neomycin (Neo) resistance
vectory only (A) or with a Bcl-2-expressing vector (B) were cultured
in the absence (Co) or presence of staurosporin (STS, 1 WM, 4 h)
or etoposide (Etop, 100 WM, 24 h). Cells were stained with an anti-
AIF antibody (revealed by a phycoerythrine conjugate; red £uores-
cence) and Sytox green (DNA-intercalating dye; green £uorescence).
Note the punctate, cytoplasmic AIF staining in untreated control
Neo cells that contrasts with the di¡use nuclear and cytoplasmic
staining in Neo cells undergong apoptosis (A). No AIF transloca-
tion was detectable in Bcl-2 overexpressing cells (B). Frequency of
AIF translocation (C) induced by staurosporin, etoposide (same
conditions as in A,B), cisplatin (Cisp; 50 WM, 24 h), melphalan
(MLP; 100 WM, 20 h), or chlorambucil (CLB; 100 WM, 20 h) in
Neo control cells (full columns) and bcl-2 transfected cells (open
columns). The percentage of cells exhibiting AIF translocation is
shown.
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When cells are induced to undergo apoptosis, AIF is re-
leased from mitochondria to the cytosol and to the nucleus.
This result has been obtained using all available methods for
the determination of the subcellular localization of AIF: in
situ immunostaining, transfection with AIF^GFP, and subcel-
lular fractionation. As an example (Fig. 4A), AIF translocates
from mitochondria (see punctate red immuno£uorescence
staining sparing the nucleus in control cells, Fig. 4A), when
apoptosis is triggered by the protein kinase inhibitor stauro-
sporin, yielding a di¡use cytoplasmic as well as nuclear stain-
ing ([15,16] and Fig. 4A). In addition, a wide array of chemo-
therapeutic agents induce the mitochondrial release of AIF in
SHEP neuroblastoma cells. This applies to the DNA-damag-
ing agent cisplatin, the topoisomerase II inhibitor etoposide,
and alkylating agents such as melphalan and chlorambucil
(Fig. 4A,C), as well as treatment with the stress-induced
pro-apoptotic second messengers ceramide and ganglioside
GD3 (not shown). The AIF translocation was inhibited by
transfection-enforced overexpression of Bcl-2, correlating
with the inhibition of chromatin condensation, one of the
hallmarks of nuclear apoptosis (revealed by DNA staining
with Sytox green; Fig. 4A^C). AIF translocation was also
observed in a variety of cell lines induced to undergo apop-
tosis, including activated peripheral blood T-lymphocytes,
CEM and Jurkat lymphoma cells, HeLa cervix carcinoma
cells, COS renal cells, and ¢broblasts [15,16,21^25]. In con-
clusion, it appears probable that AIF translocation invari-
antly accompanies apoptosis.
Kinetic studies performed in staurosporin-treated Rat-1
cells revealed that the release of AIF precedes that of full-
blown nuclear apoptosis. In this model, the release of AIF
occurs concomitantly with the dissipation of the mitochon-
drial inner transmembrane potential, and shortly before the
release of cytochrome c is detectable by in situ immuno£uo-
rescence [15,16]. The early signs of nuclear nuclear apoptosis
(stage I) consist in rippled nuclear contours and a rather par-
tial chromatin condensation. It appears that AIF is fully
translocated during this early stage, when the cytochrome c
release is still incomplete. Only at a later stage of nuclear
apoptosis (stage II), with a marked peripheral chromatin con-
densation and formation of nuclear bodies, both AIF and
cytochrome c are released from mitochondria. Pharmacolog-
ical caspase inhibition arrests nuclear apoptosis at the stage I
of apoptosis, yet does not a¡ect the release of AIF and cyto-
chrome c. Based on these data, it can be speculated that the
(caspase-independent) stage I of chromatin condensation in-
volves the translocation of AIF from mitochondria to the
nucleus, whereas the (caspase-dependent) stage II relies on
caspase activation by cytochrome c [15,16].
5. Apoptogenic e¡ects of ectopic AIF
If microinjected into the cytoplasm of normal cells, re-
combinant AIF su⁄ces to cause three hallmarks of apoptosis,
namely (1) the dissipation of the mitochondrial transmem-
brane potential and the release of cytochrome c, (2) the con-
densation of nuclear chromatin, (3) and the exposure of phos-
phatidylserine on the plasma membrane surface [15,21,25].
These alterations are rapid (30^120 min) and are not pre-
vented by addition of the pan-caspase inhibitor Z-VAD.fmk
[15,25]. Moreover, they are not a¡ected by overexpression of
the anti-apoptotic protein Bcl-2 [15]. Similar in vivo e¡ects
have been obtained by transfection-enforced overexpression
of a truncated AIF^GFP construct lacking the N-terminal
MLS (AIF^GFPv1^100) and that is misdirected to the ex-
tra-mitochondrial compartment [21]. These data con¢rm
that ectopic (extra-mitochondrial) AIF is a caspase-indepen-
dent e¡ector of apoptosis that acts beyond the Bcl-2-con-
trolled checkpoint of cell death. Is AIF required for apoptosis
to occur? This question has been addressed by microinjecting
a speci¢c antiserum into the cytoplasma of Rat-1 cells treated
with staurosporin [15]. This manipulation prevents the stau-
rosporin-induced nuclear apoptosis. Control experiments in-
volving a pre-immune antiserum or an anti-AIF antibody
blocked by pre-incubation with the AIF-derived immunogenic
peptides yielded no inhibition of staurosporin-stimulated
apoptosis [15]. Thus, at least in some pathways of apoptosis
induction, AIF is both su⁄cient and required to induce apop-
tosis (Table 1).
The apoptogenic e¡ects of AIF, as revealed in intact cells,
have been recapitulated in cell-free systems. As discussed
above, addition of recombinant AIF to puri¢ed nuclei causes
chromatin condensation [15]. This is accompanied by a large-
scale DNA fragmentation, but not by oligonucleosomal DNA
fragmentation. In intact cells, Z-VAD.fmk prevents oligonu-
cleosomal DNA degradation, yet frequently has no e¡ect on
the large-scale fragmentation pattern [16]. These results are
compatible with the hypothesis that AIF is (one of) the medi-
ator(s) responsible for large-scale chromatin degradation. In
the cell-free system, the nuclear e¡ects of AIF are observed in
the absence of cytosolic extracts, indicating that AIF acts on
one or several yet unidenti¢ed sessile nuclear target molecules.
In strict contrast, AIF has no direct e¡ect if added to puri¢ed
mitochondria in vitro. To reproduce the membrane-permeabi-
lizing e¡ects of AIF in such a system, a cytosolic heat-labile
factor must be added together with AIF [15]. In the presence
of cytosol, AIF causes mitochondria to release cytochrome c
and to lose their transmembrane potential [15]. Thus, AIF has
indirect e¡ects on the integrity of mitochondrial membranes.
Table 1
E¡ects of AIF and AIF neutralization on apoptosis induction
Experimental system Observations
AIF microinjection Loss of mitochondrial transmembrane potential
Release of cytochrome c from mitochondria
Release of AIF^GFP fusion protein from mitochondria
Nuclear chromatin condensation (stage I)
Phosphatidylserine exposure
E¡ects not inhibited by Z-VAD.fmk or Bcl-2
Overexpression of AIF lacking MLS by transfection Nuclear chromatin condensation (stage I+II)
Z-VAD.fmk arrests at stage I
No inhibitory e¡ect of Bcl-2
Injection of anti-AIF antibody into cells Inhibition of nuclear apoptosis induced by staurosporin or actractyloside
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6. Open questions and perspectives
The available data suggest that AIF has two opposite func-
tions. On the one hand, AIF is likely to serve as a vital
protein, presumably via its oxidoreductase function. The de-
tailed characterization of the redox reactions catalyzed by
AIF, as well as the thorough investigation of cells in which
AIF has been knocked out by homologous recombination
should shed some light on the question why AIF is important
for normal cell survival. Alternatively, AIF appears to be a
lethal factor as soon as it is released from the mitochondrial
intermembrane space, the compartment to which it usually is
con¢ned. How AIF mediates this apoptogenic function re-
mains entirely elusive. Thus, the functional relationship be-
tween AIF and other factors involved in chromatin conden-
sation and degradation (caspases, CAD, acinus, cyclophilin
etc.) remains unknown [26]. Moreover, the AIF-interacting
protein(s) in the cytosol (which are required for its membrane
permeabilizing e¡ects) and the nuclear AIF target(s) have not
yet been identi¢ed. Based on our knowledge of other mito-
chondrial proteins and their pro-apoptotic e¡ects, it may be
speculated that endogenous AIF inhibitors exist. Such in-
hibitors would prevent accidental cell death induction by par-
tial AIF release and set the threshold at which AIF levels
su⁄ce to drive the full cell death program. It is tempting to
speculate that the identi¢cation of AIF targets and AIF
inhibitors may lead to the generation of a new class of cyto-
toxic or cytoprotective agents. The future will reveal whether
AIF itself will be useful as a caspase-independent, Bcl-2-inde-
pendent death inducer, for instance for the gene therapy of
cancer.
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